Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Inhibiting menin attenuates high-fat diet–induced weight gain by limiting intestinal lipid absorption in mice
Xiaoru Cao, Pingping Zhou, Haiyue Meng, Zhitao Guo, Yan Cao, Chenghao Wang, Lulu Liu, Yinghao Guo, Yue Wang, Guoshun Xin, Dabin Liu, Feng Geng, Jian Ma
Xiaoru Cao, Pingping Zhou, Haiyue Meng, Zhitao Guo, Yan Cao, Chenghao Wang, Lulu Liu, Yinghao Guo, Yue Wang, Guoshun Xin, Dabin Liu, Feng Geng, Jian Ma
View: Text | PDF
Research Article Gastroenterology Metabolism

Inhibiting menin attenuates high-fat diet–induced weight gain by limiting intestinal lipid absorption in mice

  • Text
  • PDF
Abstract

Intestinal lipid metabolism is essential for systemic energy homeostasis, and its modulation is emerging as a therapeutic strategy for obesity. Menin, encoded by the MEN1 gene, is a scaffold protein that regulates chromatin remodeling and gene expression and is abundantly expressed in intestinal epithelial cells (IECs), but its metabolic role remains underexplored. Here, we generated IEC-specific Men1-knockout mice and found that Men1 deficiency protected against high-fat diet–induced obesity, accompanied by elevated carboxylesterase 1 (CES1) expression in IECs. Increased CES1 promoted triglyceride (TG) hydrolysis and reduced intracellular TG storage, thereby limiting the lipid substrate pool required for ApoB48-dependent chylomicron assembly. Although lipid hydrolysis was enhanced, steady-state free fatty acid levels were not increased; instead, Men1 deficiency activated fatty acid β-oxidation programs and increased etomoxir-sensitive fatty acid–dependent mitochondrial respiration, supporting enhanced fatty acid catabolism. Mechanistically, menin recruited histone deacetylase 1 and interacted with the nuclear receptor liver X receptor-β to suppress Ces1g transcription, thereby sustaining efficient intestinal lipid absorption. Pharmacological inhibition of menin with MI-463 recapitulated the metabolic effects of inducible Men1 deletion. In a human gut organoid-on-chip system, MI-463 dose-dependently increased CES1 expression and markedly reduced lipid accumulation. Collectively, our findings identify menin as a regulator of intestinal lipid metabolism and suggest menin inhibition as a potential therapeutic strategy for obesity-related metabolic disorders.

Authors

Xiaoru Cao, Pingping Zhou, Haiyue Meng, Zhitao Guo, Yan Cao, Chenghao Wang, Lulu Liu, Yinghao Guo, Yue Wang, Guoshun Xin, Dabin Liu, Feng Geng, Jian Ma

×

Figure 6

Pharmacological or genetic inhibition of intestinal menin attenuates HFD-induced weight gain in mice.

Options: View larger image (or click on image) Download as PowerPoint
Pharmacological or genetic inhibition of intestinal menin attenuates HFD...
(A) Men1fl/fl and Men1ΔIEC-IND mice were fed an HFD from 6 weeks of age, treated with tamoxifen (0.2 mg/g/d) for 5 days beginning at 12 weeks, and analyzed at 19 weeks. (B) Immunoblotting of menin and CES1 in IECs. (C) Body weight change after TAM. (D and E) Serum TG levels during the FTT and AUC. (F and G) Nile Red staining and quantification of lipid accumulation in proximal IECs. Five randomly selected fields per mouse were averaged as 1 data point. Scale bars: 50 μm. (H and I) Ces1g mRNA and menin/CES1 protein levels in MI-463–treated MODE-K cells. (J) Co-IP of Flag-menin and HA-LXRβ in MI-463–treated HEK293T cells. (K) ChIP-qPCR analysis of menin, LXRβ, H3K27Ac, and HDAC1 occupancy at the Ces1g promoter after MI-463 treatment. (L) HFD-fed C57BL/6 mice received vehicle or MI-463 (30 mg/kg/d, oral) from 12 to 18 weeks of age. (M) Body weight changes during treatment. (N) Ces1g expression in jejunum and liver. (O and P) Serum TG levels during FTT and corresponding AUC. (Q and R) Nile Red staining and quantification of intestinal epithelial lipid accumulation. Five fields per mouse were averaged as 1 data point. Scale bars: 100 μm. (S) Serum ApoB48 levels at 6 hours during FTT. For A–G and L–R, n = 6 mice per group; for S, n = 3 mice per group; for H and K, n = 3; panels I and J show representative results from 3 independent experiments. All data are presented as mean ± SD. Statistical analysis was assessed by 2-way ANOVA for panels C, D, K, and M–O; by unpaired 2-tailed Student’s t test for panels E, G, P, and R; and by 1-way ANOVA for panel H. **P < 0.01, ***P < 0.001, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts